

**IN THE SPECIFICATION:**

Please replace the heading on Page 4, line 23, with the following: Summary of the Invention.

Please insert the following on Page 5, before line 1:

**Brief Description of the Drawings**

Figure 1. The ion-exchange fractionation profile of casein (Fig. 1A) and commercial human alpha-lactalbumin (Fig. 1B). The arrow represents the time point at which 1 M NaCl was applied.

Figure 2. Gel chromatographic fractionation profiles of pool VI obtained from fractionation of casein (Fig. 2A) and human alpha-lactalbumin before ion-exchange chromatography (Fig. 2B).

Figure 3. Ion-exchange fractionation profile of pool LA<sub>2</sub> obtained after ion-exchange chromatography of alpha-lactalbumin.

Figure 4. Mass spectrometry of ALLP.

**Detailed Description of the Invention--**

Please replace the paragraph beginning on Page 14, line 34 and ending on Page 15, line 3 with the following:

A dose response curve was made up based on the bactericidal effect on S. pneumoniae 10175 at different levels of administration of ALLP compared with control (no

addition). thereby ALLP was administered at 0.1 mg/ml, 0.5 mg/ml, and 1.0 mg/ml, respectively. ~~The graph obtained is shown in FIG. 5. As evident therefrom as~~ As little as 0.1 mg/ml of ALLP provides a bactericidal effect on S. pneumoniae.

Please replace the paragraph beginning on Page 15, line 5 with the following:

The viable counts were further determined using different control proteins, viz. bovine serum albumine (BSA), alphalactalbumine (bovine origin), lactoferrin (bovine origin) in a concentration of 10 mg/ml, and control (no protein). ~~As evident from FIG. 6 these~~ These proteins had no bactericidal effect on S. pneumoniae 10175.